Currently also: Chief Informatics and Technology Officer (CITO) at Pangea Botanica, London/UK and Berlin/Germany
Previous positions:
Director Digital Chemistry at NUVISAN Berlin
Associate Director Computational ADME and Safety (Clinical Pharmacology & Safety Sciences/Data Science and Artificial Intelligence - CPSS/DSAI) at AstraZeneca Cambridge
Co-founder of Healx Ltd.
Co-founder of PharmEnable Ltd.
- Committed to developing new life science data analysis methods (AI/ML/data science) and their application, primarily related to chemical biology, drug discovery and in silico toxicology
- Expertise comprises data ranging from chemical structure and gene expression data to phenotypic readouts and preclinical information, applied to both efficacy- and safety/tox-related questions
- Collaborating with academic research groups, as well as pharmaceutical, chemical, and consumer goods companies (Eli Lilly, AstraZeneca, GSK, BASF, Johnson&Johnson/Janssen, Unilever, ...)
- Co-founder/founding CTO and current SAB member of Healx Ltd. (data-driven drug repurposing for rare diseases, and beyond); co-founder of PharmEnable Ltd.; SAB member of Lhasa Ltd. (toxicology and metabolism prediction) and Cresset Ltd.
- Coordinator of the Computational & In Silico Toxicology Specialty Section of the British Toxicology Society (BTS)
- Steering Committee Member of the Cambridge Alliance on Medicines Safety (CAMS)
- Currently leading a group of ca. 15 PhD students, postdocs, project students and visitors at the Centre for Molecular Informatics at the University of Cambridge, https://www-cmi.ch.cam.ac.uk/centre-molecular-informatics
Publications
KekuleScope: prediction of cancer cell line sensitivity and compound potency using convolutional neural networks trained on compound images
Journal of Cheminformatics
(2019)
11
41
(doi: 10.1186/s13321-019-0364-5)
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
Nature Communications
(2019)
10
2674
(doi: 10.1038/s41467-019-09799-2)
Leveraging heterogeneous data from GHS toxicity annotations, molecular and protein target descriptors and Tox21 assay readouts to predict and rationalise acute toxicity.
Journal of Cheminformatics
(2019)
11
36
(doi: 10.1186/s13321-019-0356-5)
Characterizing ABC-Transporter Substrate-Likeness Using a Clean-Slate Genetic Background.
Frontiers in Pharmacology
(2019)
10
448
(doi: 10.3389/fphar.2019.00448)
Sulfated Ceria Catalyzed Synthesis of Imidazopyridines and Their Implementation as DNA Minor Groove Binders.
Chemistry and Biodiversity
(2019)
16
e1800435
(doi: 10.1002/cbdv.201800435)
Synthesis of C–C, C–N coupled novel substituted dibutyl benzothiazepinone derivatives and evaluation of their thrombin inhibitory activity
Bioorganic Chemistry
(2019)
87
142
(doi: 10.1016/j.bioorg.2019.03.004)
Prediction of UGT-mediated Metabolism Using the Manually Curated MetaQSAR Database
ACS medicinal chemistry letters
(2019)
10
633
Correction to: Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson's disease: A comparison of 33 human and animal studies (BMC Neurology (2017) 17 (58) DOI: 10.1186/s12883-017-0838-x)
BMC Neurol
(2019)
19
16
(doi: 10.1186/s12883-019-1240-7)
Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis
Journal of Crohn's and Colitis
(2019)
13
S006
(doi: 10.1093/ecco-jcc/jjy222.009)
P011 Signalling and transcriptional network propagation uncovers novel ulcerative colitis pathogenetic pathways from single-nucleotide polymorphisms
Journal of Crohn's and Colitis
(2019)
13
s091
(doi: 10.1093/ecco-jcc/jjy222.135)
- ‹ previous
- Page 12
